Der Orthopäde

, Volume 40, Issue 12, pp 1111–1118

Bisphosphonatinduzierte Stressfrakturen am Femur

Ein neues Problem und bisherige Erkenntnisse – Fallbericht
  • R. Lenz
  • M. Ellenrieder
  • R. Skripitz
  • R. Bader
  • C. Pautke
  • W. Mittelmeier
  • T. Tischer
Kasuistiken

Zusammenfassung

Die Behandlung der unterschiedlichen Osteoporoseformen durch Bisphosphonate hat sich als sichere und effektive Therapie erwiesen. In den letzten Jahren wurde allerdings über seltene unerwünschte Komplikationen in der Langzeitbehandlung berichtet. Insbesondere das Auftreten atypischer subtrochantärer Frakturen rückte zunehmend in den klinischen Fokus. Dennoch fand diese Problematik kaum Berücksichtigung in der wissenschaftlichen Diskussion. Anhand eines Fallberichts und Darstellung des aktuellen Literaturstandes soll diese Thematik mit dem Ziel einer früheren Diagnosestellung und Therapie dieser Komplikation aufgegriffen werden.

Schlüsselwörter

Bisphosphonate Komplikationen Subtrochantäre Frakturen Osteoporose Atypische Frakturen 

Biphosphonate-induced femoral stress fractures

A new problem and knowledge so far – case report

Abstract

During the last several years the treatment of osteoporosis with bisphosphonates has become accepted as a safe and effective procedure. However, recently there have been increasing numbers of reports of rare complications in the literature. Particularly the occurrence of atypical fractures of the femur has become a focus of interest but the problem is insufficiently known and only rarely addressed in the scientific discussion. The case illustrated here and a survey of the important facts in the recent literature highlight essential aspects of long-term bisphosphonate therapy.

Keywords

Bisphosphonates Complications Subtrochanteric fractures Osteoporosis Atypical fractures 

Literatur

  1. 1.
    Black D, Cummings S, Karpf D (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535–1541PubMedCrossRefGoogle Scholar
  2. 2.
    Bone H, Hosking D, Devogelaer J (2004) Ten years‘ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350:1189–1199PubMedCrossRefGoogle Scholar
  3. 3.
    S3-Leitlinie Osteoporose. Dachverband Osteologie eV (DVO). http://www.dv-osteologie.org 2009Google Scholar
  4. 4.
    Rogers M, Brown R, Hodkin V et al (1996) Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 224:863–869PubMedCrossRefGoogle Scholar
  5. 5.
    Luckman S, Hughes D, Coxon F (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Mineral Res 13:581–589CrossRefGoogle Scholar
  6. 6.
    Watts N, Diab D (2010) Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 95:1555–1565PubMedCrossRefGoogle Scholar
  7. 7.
    Abrahamsen B (2010) Bisphosphonate adverse effects, lessons from large databases. Curr Opin Rheumatol 22:404–409PubMedCrossRefGoogle Scholar
  8. 8.
    Otto S, Abu-Id M, Fedele S et al (2011) Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence – a multi-centre study. J Craniomaxillofac Surg 39:272–277PubMedCrossRefGoogle Scholar
  9. 9.
    Koh J, Goh S, Png M et al (2010) Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture. J Orthop Trauma 24:75–81PubMedCrossRefGoogle Scholar
  10. 10.
    Kwek E, Goh S, Koh J et al (2008) An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 39:224–231PubMedCrossRefGoogle Scholar
  11. 11.
    Black D, Kelly M, Genant H et al (2010) Bisphosphonates an fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 362:1761–1771PubMedCrossRefGoogle Scholar
  12. 12.
    Russell R, Watts N, Ebetino F, Rogers M (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759PubMedCrossRefGoogle Scholar
  13. 13.
    Odvina C, Zerwekh J, Rao D et al (2005) Severely suppressed bone turnover: potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294–1301PubMedCrossRefGoogle Scholar
  14. 14.
    Armamento-Villareal R, Napoli N, Diemer K et al (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures recieving bisphosphonates: a case series. Calcif Tissue Int 85:37–44PubMedCrossRefGoogle Scholar
  15. 15.
    Currey J (1984) Effects of differences in mineralization on the mechanical properties of bone. Philos Trans R Soc Lond B Biol Sci 304:509–518PubMedCrossRefGoogle Scholar
  16. 16.
    Richer E, Lewis M, Odvina C et al (2005) Reduction in normalized bone elasticity following long-term bisphosphonate treatment as measured by ultrasound critical angle reflectometry. Osteoporos Int 16:1384–1392PubMedCrossRefGoogle Scholar
  17. 17.
    Mashiba T, Mori S, Burr D (2005) The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab 23:36–42PubMedCrossRefGoogle Scholar
  18. 18.
    Mashiba T, Turner C, Hirano T (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524–531PubMedCrossRefGoogle Scholar
  19. 19.
    Ciarelli T, Fyhrie D, Parfitt A (2003) Effects of vertebral bone fragility and bone formation rate on the mineralization levels of cancellous bone from white females. Bone 32:311–315PubMedCrossRefGoogle Scholar
  20. 20.
    Boivin G, Chavassieux P, Santora A et al (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687–694PubMedCrossRefGoogle Scholar
  21. 21.
    Chaiamnuay S, Saag K (2006) Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 7:101–112PubMedCrossRefGoogle Scholar
  22. 22.
    Boonen S, Laan R, Barton I, Watts N (2005) Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int 16:1291–1298PubMedCrossRefGoogle Scholar
  23. 23.
    Lo J, O’Ryan F, Gordon N et al (2010) Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure. J Oral Maxillofac Surg 68:243–253PubMedCrossRefGoogle Scholar
  24. 24.
    Ensrud K, Black D, Palermo L et al (1997) Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 157:2617–2624PubMedCrossRefGoogle Scholar
  25. 25.
    Goddard M, Reid K, Johnston J, Khanuja H (2009) Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics 32:607CrossRefGoogle Scholar
  26. 26.
    Pauwels F (1948) Die Bedeutung der Bauprinzipien des Stütz- und Bewegungsapparates für die Beanspruchung langer Röhrenknochen. Z Anat 114:129–166CrossRefGoogle Scholar
  27. 27.
    Breglia M, Carter J (2010) Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol 16:76–78PubMedCrossRefGoogle Scholar
  28. 28.
    Neviaser A, Lane J, Lenart B et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350PubMedCrossRefGoogle Scholar
  29. 29.
    Lenart B, Lorich D, Lane J (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306PubMedCrossRefGoogle Scholar
  30. 30.
    Bamrungsong T, Pongchaiyakul C (2010) Bilateral atypical femoral fractures after long-term alendronate therapy: a case report. J Med Assoc Thai 93:620–624PubMedGoogle Scholar
  31. 31.
    Capeci C, Tejwani N (2009) Bilateral low-energy simultaneous or sequential femoral fractures. J Bone Joint Surg [Am] 91:2556–2561Google Scholar
  32. 32.
    Goh S, Yang K, Koh J (2007) Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg [Br] 89:349–353Google Scholar
  33. 33.
    Visekruna M, Wilson D, McKiernan F (2008) Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 93:2948–2952PubMedCrossRefGoogle Scholar
  34. 34.
    Schwartz A, Bauer D, Cummings S et al (2010) Efficacy of continued alendronate for fractures in women with and without prevalent fracture: the FLEX trial. J Bone Min Res 25:976–982CrossRefGoogle Scholar
  35. 35.
    Giusti A, Hamdy N, Papapoulos S (2010) Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 47:169–180PubMedCrossRefGoogle Scholar
  36. 36.
    Sayed-Noor A, Sjödén G (2009) Case reports: two femoral insufficiency fractures after long-term alendronate therapy. Clin Orthop Relat Res 467:1921–1926PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • R. Lenz
    • 1
  • M. Ellenrieder
    • 1
  • R. Skripitz
    • 1
  • R. Bader
    • 1
  • C. Pautke
    • 2
  • W. Mittelmeier
    • 1
  • T. Tischer
    • 1
  1. 1.Orthopädische Klinik und PoliklinikUniversitätsklinikum RostockRostockDeutschland
  2. 2.Klinik für Mund-, Kiefer-, GesichtschirurgieLudwig-Maximilians-UniversitätMünchenDeutschland

Personalised recommendations